Merck's rolofylline misses heart failure endpoint

Merck & Co. Inc. (NYSE:MRK) said preliminary data from the Phase III PROTECT trial showed that 30 mg IV rolofylline missed the primary endpoint of improving symptoms of acute heart failure compared to...